One trick to solve the target discovery in the treatment of TILs
Time of Update: 2022-10-02
Cellular immunotherapy, also known as adoptive cellular immunotherapy (AIT), has a promising application prospect that has become the fourth pillar in the field of tumor therapy in addition to follow-
Courier! Eli Lilly PD-1 agonist is clinically declared in China
Time of Update: 2022-09-30
A monoclonal antibody that binds to and excites the PD-1 receptor, with the potential to become a "first-in-class" therapy, has completed a Phase 2 clinical trial overseas for the treatment of rheumatoid arthritis Screenshot source: CDE official website The PD-1 target has played an extremely important role in tumor treatment.
Top biotechnology financing list released
Time of Update: 2022-06-09
Judging from the 2021 list of the top 10 private financing of biotechnology companies screened by Fierce Biotech, cell and gene therapy (CGT) is a hot spot for financing, and new crown vaccines and therapeutic products, and AI pharmaceuticals are also favored by capital .
Notice of the State Food and Drug Administration on Issuing the Catalogue of Generic Drug Reference Preparations (Fifty Batch) (No. 9, 2022
Time of Update: 2022-03-02
Notice of the State Food and Drug Administration on Issuing the Catalogue of Generic Drug Reference Preparations (Fifty Batch) (No.
Attachment: Catalogue of Generic Drug Reference Preparations (Fifty Batch) State Food and Drug Administration February 10, 2022 Relevant attachments serial number accessory name 1 Annex to the Circular No.
New drug application for RTK inhibitor for the treatment of renal cell carcinoma
Time of Update: 2022-01-10
Recently, Allarity Therapeutics announced that it has submitted a New Drug Application (NDA) to the US FDA to seek approval of the receptor tyrosine kinase (RTK) inhibitor dovitinib for the third-line treatment of renal cell carcinoma (RCC) .
China's self-developed ADC new drug approved for marketing for gastric cancer treatment
Time of Update: 2021-06-21
The reporter learned from the Management Committee of Yantai Development Zone on the 10th that China's first original antibody-conjugated drug (ADC) new drug-vedicitumumab, declared by Rongchang Biopharmaceutical (Yantai) Co.
The innovative anemia therapy of Baishi Meishi Guibao is to be included in the priority review
Time of Update: 2021-03-12
Transfer from | Two applications for injection at Celgene, a subsidiary of BMS, have been included in the proposed priority review list for the treatment of adult β-Thalassemia patients who need regular infusions of red blood cells (RBCs), according to the latest announcement from the Drug Review Center (CDE) of the State Drug Administration of China.
Xu Yanjun, deputy director of the National People's Social Affairs Department: How to talk about drug price negotiations
Time of Update: 2021-02-06
Recently, the Ministry of Human and Social Affairs issued the Notice on the Inclusion of 36 Drugs in the Category B of the National Basic Medical Insurance, Industrial Injury Insurance and Maternity I
Henan reported 10 batches of non-conforming samples involving condiments, edible agricultural products, pastries and other 6 categories
Time of Update: 2020-12-06
Food Partners Network News July 15, Henan Province Market Supervision Bureau informed that the bureau recently organized a sampling of condiments, soy products, edible agricultural products, meat prod
East Sunshine will take 1.5 billion anti-thrombosis drugs
Time of Update: 2020-11-08
On October 30, the official website of the State Drug Administration showed that Dongsan pharmaceutical products to imitate the 4 categories of reported Tegrelo tablets into the administrative approval stage, is expected to be approved in recent days and treated as a review.
The drug MingJuno acquires Syracuse plus-code solid tumor T cell immunotherapy development
Time of Update: 2020-07-27
On July 20, the company announced the completion of its acquisition of Syracuse Biopharma (Hong Kong) Co., Ltd and obtained a license for EUreka Therapeutics' proprietary ARTEMIS ® antibody TCR techno
"Pharmaceutical Speed Reader" step-by-step pharmaceutical sales of Hubei Kyushu Tong equity a number of pharmacies to write off the de-listing
Time of Update: 2020-07-23
Step Pharmaceuticals intends to transfer the shares of Hubei Step Long Kyushu Tong, Heng Rui and Sun Yiyang jointly invested 100 million yuan to set up a new company, and Regenerative Yuan Launch An
Please check it! Chemical registration classification and reporting information requirements
Time of Update: 2020-07-18
Introduction: Notice of the State Drug Administration on the requirements for the publication of the classification and declaration of chemical sist registration (No 44 of 2020) In cooperation with
FDA accepts new drug application for new kiozanimod for recurrent multiple sclerosis
Time of Update: 2020-06-09
recently, Celgene announced that the Us FDA (http:// has accepted the application for new drug (http:// (NDA) for the treatment of recurrent multiple sclerosis (RMS), and the European Medicin
Treatment of multiple myeloma Sanofi CD38 antibody combination therapy reaches phase 3 clinical end
Time of Update: 2020-05-30
MM is a blood cancer caused by plasma cell cancer in the bone marrow Abnormal plasma cells accumulate in the bone marrow and produce tumors in multiple bones in the body Not only do these cells not fu